Reforms to the regulation of patient-specific access to therapeutic products have been implemented in response to the recommendations arising from the Review of Medicines and Medical Devices Regulation.
The reforms include modifications to the Special Access Scheme and Authorised Prescriber scheme to allow streamlined access to certain unapproved therapeutic products.
Introduction of a notification pathway, rather than the standard pre-approval pathway, that allows certain types of health practitioners to supply unapproved therapeutic goods considered to have an established history of use.
Introduction of an online system to enable the electronic submission of Special Access Scheme applications and notifications.
Changes to the Authorised Prescriber Scheme allowing for a more streamlined application process to improve access to required unapproved therapeutic goods.